Top Markets
#1 Black Phoenix Black Phoenix +820.83%
#2 Tutorial Tutorial +25.27%
#3 Beam Beam +25.04%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.53%
#5 MiL.k Alliance MiL.k Alliance +20.24%
#6 SAFEcoin SAFEcoin +18.55%
#7 Bless Bless +18.33%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +15.85%
#9 THORChain THORChain +15.63%
#10 Magma Finance Magma Finance +15.39%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Kailera Therapeutics, Inc. Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc.

KLRA
Rank in Stocks #5874
Kailera Therapeutics is a biopharmaceutical company currently advancing through... Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.
Share Price
$18.35
Last synced: 2026-08-26
Market Cap
$2.38B
Change (1 day)
3.35%
Change (1 year)
-
Country
US
Trade Kailera Therapeutics, Inc. (KLRA)

Category

Healthcare
Revenue for Kailera Therapeutics, Inc. (KLRA)
Revenue in Aug 2026 TTM: 0
According to Kailera Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Kailera Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH